CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Dabigatran etexilate

Last Updated: May 31, 2010
Result type: Reports
Project Number: SR0202-000
Product Line: Reimbursement Review

Generic Name: Dabigatran etexilate

Brand Name: Pradaxa

Manufacturer: Boehringer-Ingelheim (Canada) Ltd.

Therapeutic Area: Atrial fibrillation prevention of stroke and systemic embolism

Indications: Atrial fibrillation prevention of stroke and systemic embolism

Submission Type: Initial

Project Status: Cancelled

Patient Input Important Notice: /cdr/patient-group-input/important-notice